Whitaker T

Whitaker, MD, Chief Medical Officer, Head of Research & Development, Seelos Therapeutics, Inc., New York, NY.

1 paper

ArticleKetamine

A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide.

Whitaker T, Farrand KF, Thase ME